



HHS Public Access

Author manuscript

Acta Psychiatr Scand. Author manuscript; available in PMC 2023 June 01.

Published in final edited form as:

Acta Psychiatr Scand. 2022 June ; 145(6): 544–556. doi:10.1111/acps.13409.

Antidepressant use during pregnancy and risk of adverse neonatal outcomes: a comprehensive investigation of previously identified associations

Anna-Sophie Rommel, PhD^{1,*}, Natalie C. Momen, PhD², Nina Maren Molenaar, MD, PhD¹, Esben Agerbo, DrMedSc, PhD^{2,3,4}, Veerle Bergink, MD, PhD^{1,5,6}, Trine Munk-Olsen, PhD^{2,7}, Xiaoqin Liu, PhD²

¹Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, New York, 10029, USA.

²NCRR-The National Centre for Register-based Research, Aarhus University, 8210 Aarhus, Denmark

³CIRRAU - Centre for Integrated Register-Based Research at Aarhus University, 8210 Aarhus, Denmark

⁴iPSYCH-Lundbeck Foundation Initiative for Integrative Psychiatric Research, 8210 Aarhus, Denmark

⁵Department of Psychiatry, Erasmus Medical Centre Rotterdam, 3015 Rotterdam, The Netherlands.

⁶Department of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York City, New York, 10029, USA.

⁷Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark

Abstract

Objective: Prenatal antidepressant use is widespread. Observational studies have investigated the neonatal effects of prenatal antidepressant exposure with inconclusive results. We aimed to comprehensively investigate the associations between prenatal antidepressant exposure and the most commonly studied adverse neonatal outcomes: preterm birth, birthweight, poor neonatal adaptation, persistent pulmonary hypertension of the neonate (PPHN), neonatal admission and congenital malformations.

Methods: We included 45,590 singletons (born 1997–2015) whose mothers used antidepressants within one year before pregnancy. Children were categorised into two groups: continuation

*Corresponding author: Anna-Sophie Rommel, Icahn (East) Building Floor 4, 1425 Madison Ave, New York, NY 10029, anna.rommel@mssm.edu.

Contributors: ASR, NCM, NMM, EA, VB, TM-O, and XL conceived and designed the study. ASR drafted the manuscript. XL had full access to the data, analysed the data, and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors interpreted the data and revised the manuscript critically.

Conflict of Interest: All authors declare: support for the submitted work as described below; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

(antidepressant use before and during pregnancy) or discontinuation (antidepressant use before but not during pregnancy). We applied random-effects logistic and linear regressions, adjusting for covariates.

Results: After adjusting for confounders, prenatal antidepressant exposure was associated with a 2.3 day (95% CI -2.9; -2.0) decrease in gestational age and a 51g (95% CI -62g; -41g) decrease in birthweight. The continuation group was at increased risk for moderate-to-late preterm birth (32–37 weeks) (aOR=1.43; 95%CI 1.33; 1.55), moderately low birthweight (1,500–2,499g) (aOR=1.28; 95%CI 1.17; 1.41), postnatal adaptation syndrome (aOR=2.59; 95%CI 1.87; 3.59) and neonatal admission (aOR=1.52; 95%CI 1.44; 1.60) compared to the discontinuation group.

Conclusion: Prenatal antidepressant exposure was associated with small decreases in gestational age and birthweight, as well as higher risk for moderate-to-late preterm birth, moderately low birthweight, neonatal admission and postnatal adaptation syndrome. No differences in risk were found for PPHN, or congenital malformations. The causality of the observed associations cannot be established due to the potential for unmeasured residual confounding linked to the underlying disease.

Keywords

Antidepressants; Perinatal Depression; Neonatal outcomes; Preterm Birth; Low Birthweight

Introduction

Depression and anxiety during pregnancy and after delivery impact around 12% of new mothers worldwide.¹ Children of individuals who suffered from depression during pregnancy have an increased risk of being born preterm and with low birthweight.² Maternal perinatal depression can also lead to behavioural, emotional, cognitive and motor problems in early childhood.³ Antidepressants are the first-line treatment for depression and anxiety,⁴ with many patients using them long-term as maintenance treatment to prevent relapse⁵. Therefore, antidepressant use during pregnancy is widespread, with prevalence estimates ranging between 2% and 13%.⁶ Yet, antidepressants cross the placenta and the blood-brain barrier⁷ and, out of fear for the potential negative consequences to their child, approximately 50% of pregnant individuals decide to discontinue their antidepressants before or during pregnancy⁸. Numerous observational studies have investigated the effects of prenatal exposure to antidepressants, albeit with inconclusive results. Some studies have found maternal antidepressant use to be associated with increased risks for preterm delivery,⁹ low birthweight,⁹ poor neonatal adaptation,¹⁰ persistent pulmonary hypertension of the neonate (PPHN)¹¹ and congenital malformations;¹² while other studies did not find these increased risks or observed only modest effects.^{13–15} Several of these studies failed to adjust for important confounders, such as smoking, maternal mental illness or other associated chronic conditions. Furthermore, few sought to assess the effects of antidepressant exposure against exposure to untreated maternal depression, i.e., confounding by indication.¹⁶

Most research indicates that prenatal antidepressant exposure is associated with preterm birth (<37 weeks gestation) and gestational age at birth.¹⁷ A meta-analysis of 28 studies (N=3,063,499) found that prenatal antidepressant exposure increases the risk of preterm

birth by ~70% (relative risk [RR]=1.69, 95% CI=1.52; 1.88).⁹ Another meta-analysis of 41 observational studies (N=5,335,547) suggested that the effects of antidepressants on gestational age may be related to the timing of exposure.¹⁸ Controlling for confounding factors (e.g., maternal age, smoking, alcohol use and previous preterm birth), the authors found that third trimester antidepressant exposure (OR=1.96; 95% CI=1.62; 2.38), but not exposure in the first trimester (OR=1.16; 95% CI=0.92;1.4), was associated with preterm birth.¹⁸ However, heterogeneity across studies in all three meta-analyses was large, indicating that the variability of the results across the included studies was high. Moreover, the meta-analyses found evidence of possible publication bias, suggesting that studies with negative findings may not have been published.⁹ Lastly, most studies compared children exposed to antidepressants in utero to unexposed children, thus failing to properly address confounding by indication.¹⁸

Evidence for an association between prenatal antidepressant exposure and birthweight remains inconclusive. One meta-analysis of 15 studies (N=3,001,041) found that prenatal exposure to antidepressants was associated with low birthweight (<2,500 g) (RR=1.44; 95% CI=1.21; 1.70), although heterogeneity across studies was significant.⁹ Another meta-analysis of 20 studies (N=1,438,994) reported that birthweight was decreased in children prenatally exposed to antidepressants compared to unexposed children (mean difference [MD]= -74g; 95% CI= -117g; -31g).¹⁹ Yet, when children prenatally exposed to antidepressants were compared to children prenatally exposed to maternal depression (six studies, N=165,268), the mean difference was close to zero (MD= -0.10g; 95% CI= -0.16g; -0.03g), with high precision and little heterogeneity.¹⁹

Low-strength evidence seems to provide support for an association between exposure to antidepressants during pregnancy and overall occurrence of poor neonatal adaptation (PNA). Although definitions vary, symptoms of PNA include agitation and restlessness, irritability, insomnia, hypoglycaemia, hypothermia, respiratory distress, altered muscle tone, convulsions/seizures, and feeding problems. The reported incidence of PNA among infants prenatally exposed to antidepressants ranges from 5% to 85%, with the variability possibly explained by different studies applying different definitions.²⁰ According to a meta-analysis of eight observational studies (N=959 infants), PNA is more likely to occur in neonates prenatally exposed to antidepressants than unexposed neonates (OR=5.07; 95% CI=3.25; 7.90).²⁰ A more recent meta-analysis comparing infants prenatally exposed to antidepressants compared to healthy controls (N=23,231 exposed infants), showed increased risk for convulsions (OR=3.25; 95% CI=1.76; 6.02); hypoglycaemia (OR=1.65; 95% CI=1.53; 1.78), respiratory problems (OR=1.96; 95% CI=1.80; 2.14), temperature dysregulation (OR=1.75; 95% CI=1.20; 2.55) and feeding problems (OR=2.25; 95% CI=1.08; 4.69).¹⁰ However, few studies in this field sufficiently control for bias, including confounding due to indication, disease-related moderators, socioeconomic status, ethnicity, somatic health or other known risk factors for adverse neonatal outcome.¹⁰

Multiple studies have found a link between antidepressant use during late pregnancy (i.e., third trimester) and a small absolute increase of persistent pulmonary hypertension of the newborn (PPHN), a potentially fatal condition that occurs in ~2 per 1000 live births in the general population.²¹ However, research has yielded conflicting results which may reflect

differences in methodology, particularly a failure to address confounding by indication.¹¹ The most recent meta-analysis of 11 observational studies compared children who were prenatally exposed to antidepressants during any trimester (n=156,978) to unexposed children (n=6,923,872).¹¹ The incidence of PPHN in exposed and unexposed children was 2.9 in 1000 and 1.8 in 1000, respectively. The number needed to harm was 1000, meaning that antidepressants were associated with one additional case of PPHN for every 1000 children prenatally exposed to antidepressants and 1000 unexposed children. The risk of PPHN was greater in the children prenatally exposed to antidepressants than unexposed children (OR=1.82, 95% CI=1.31; 2.54). However, heterogeneity across studies was high and confounding by indication has not yet been addressed.¹¹

Prenatal exposure to antidepressants may further be associated with admission to the neonatal intensive care unit (NICU).²² In a recent meta-analysis, admission to the NICU was analysed in 13 highly heterogeneous studies (n=22,396 exposed infants). The meta-analysis revealed a higher risk of NICU admission in infants prenatally exposed to antidepressants compared to unexposed infants (OR=1.74; 95 % CI=1.43; 2.11), as well as to infants born to depressed but untreated mothers (OR=2.64; 95 % CI=1.58; 4.40).¹⁰

Most research indicates that antidepressants as a group are not teratogenic.^{23–29} However, the risk of congenital malformations in exposed children has been the subject of discussion and controversy.¹² A recent meta-analysis of 29 cohort studies (N=9,085,954) found that prenatal antidepressant exposure was associated with an increased risk of overall major congenital anomalies (MCAs) (RR=1.11; 95% CI=1.03; 1.19) and congenital heart defects (CHD) (RR=1.24; 95% CI=1.11; 1.37) compared to the general population. However, when the analysis was restricted to children of women with a psychiatric diagnosis (MCAs: RR=1.04; 95% CI=0.95; 1.13; CHD: RR=1.06; 95% CI=0.90; 1.26), no significantly increased risk was observed.¹²

In summary, none of the aforementioned associations are supported by convincing evidence, although suggestive evidence exists for some, including preterm birth. Conflicting findings may be the result of varying study designs, exposure times, and a failure to address confounding factors such as lifestyle factors, socioeconomic factors, and confounding by indication.¹⁴

Aims of the study

The aim of the current prospective population-based register study was to conduct a comprehensive investigation of the associations between prenatal antidepressant exposure and the most commonly investigated adverse neonatal outcomes:³⁰ gestational age, preterm birth, low birthweight and small for gestational age (SGA), poor neonatal adaptation, persistent pulmonary hypertension of the neonate (PPHN), neonatal admission and congenital malformations, controlling for important confounding factors.

Methods

Study population

We carried out a population-based cohort study using data from the Danish national registers.³¹ All residents in Denmark are assigned a unique identification number in the Danish Civil Registration System³² which permits accurate linkage of individual-level data. We first identified 1,158,082 liveborn singletons born during 1997–2015 from the Danish National Medical Birth Registry.³³ We excluded 16,248 children who had missing or unrealistic gestational age or birthweight data (gestational age <154 or >315 days; birthweight <300 or >6,400 grams), and 3,319 children with chromosomal abnormalities (the International Classification of Diseases, 10th revision (ICD-10) codes: Q90–Q99). We included a total of 1,138,515 children born to 665,051 mothers (Figure 1). Throughout this paper, we refer to pregnant and birthing individuals as ‘mothers’ for fluency and unambiguity while acknowledging that not all pregnant and birthing individuals choose this label. The study was approved by the Danish Data Protection Agency. No informed consent is required for purely register-based studies on the basis of encrypted data in accordance with the legislation in Denmark. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving human participants/patients were approved by the Danish Data Protection Agency. By Danish law, no informed consent is required for a register-based study using anonymised data.

Antidepressant exposure during pregnancy

Information on antidepressant use during pregnancy was retrieved from the Danish National Prescription Registry.³⁴ This register includes a record of all prescriptions dispensed in Denmark since 1995. For each prescription, it contains anatomical therapeutic chemical (ATC) classification codes, the number of defined daily doses per package, the number of packages dispensed, and the dispensing date. The ATC code for selective serotonin reuptake inhibitors (SSRIs) is N06AB; for non-SSRI antidepressants the ATC codes are N06AA, N06AF, N06AG and N06AX. The start of antidepressant use was indicated by the dispensing date of the first relevant prescription. We defined antidepressant use during pregnancy as at least one prescription dispensed on any date from one month before pregnancy until delivery. The start of pregnancy was ascertained using gestational age. This was primarily based on the first- or second-trimester ultrasound scan; however, when no ultrasound data were available, the first day of the mother’s last menstrual period was used.³³ To capture recent episodes, we included antidepressant prescriptions dispensed from one year up to one month before pregnancy. Children were categorized into four mutually exclusive groups according to maternal redemption of an antidepressant prescription from one year to one month before pregnancy (referred to as ‘before pregnancy’) and/or during pregnancy (Figure 1): i) unexposed, with no maternal antidepressant use before or during pregnancy; ii) discontinuation, with use before but not during pregnancy; iii) continuation, with use both before and during pregnancy; and iv) new user, with use only during pregnancy (Figure 1).

Outcomes of interest

Our primary outcomes included extremely preterm birth (gestational age <28 weeks), very preterm birth (28 to 32 weeks), moderate to late preterm birth (32 to 37 weeks), very low birthweight (<1,500 g), moderately low birthweight (1,500–2,499 g), small for gestational age (i.e., a birthweight below the 10th percentile of birthweight by gestational age and sex), persistent pulmonary hypertension of the neonate (PPHN), neonatal admission, postnatal adaptation syndrome and congenital malformations. We derived data on gestational age, birthweight and sex of the child from the Danish Medical Birth Registry. Information on postnatal adaptation syndrome, PPHN, neonatal admission and congenital malformations was obtained from the Danish National Patient Registry.³⁵ The registry contains data on inpatients since 1977; since 1995 outpatient and emergency visits are also included. Children were considered to have postnatal adaptation syndrome if they had an inpatient, outpatient or emergency hospital treatment with an ICD-10 code of P96.1. PPHN was defined as a hospital contact, with ICD-10 codes of P29.3 or I27.0, within seven days of birth. We defined neonatal admission as an inpatient contact within the first 28 days, excluding contacts with the ICD-10 codes Z38 (liveborn infants according to the place of birth and type of delivery) or Z76 (persons encountering health services in other circumstances, mainly healthy person accompanying sick person). Congenital malformations, excluding chromosomal abnormalities, were determined by 1 year of age, including all singular and combined structural defects, syndromes, sequences and associations, such as cardiovascular defects, neural tube defects, hypospadias and epispadias (ICD-10 codes Q00–Q89, excluding minor malformations according to the EUROCAT Guide 1.4) treated in the hospitals.

Potential confounders

We considered a broad range of potential confounders related to maternal characteristics in our analyses using directed acyclic graphs (see Appendix I): psychiatric history at delivery retrieved from the Danish Psychiatric Central Research Register³⁶ (ICD-8 codes 290–315; ICD-10 codes F00–F99); age at delivery (<25 years, 25–34 years, 35 years); primiparity (yes/no); inpatient and outpatient psychiatric treatment from one year before pregnancy until delivery (yes/no); prescriptions for other psychotropic drugs (ATC codes N05 and N06 excluding N06A) during pregnancy (from one month prior to pregnancy until delivery; yes/no); prescriptions for antiepileptic drugs (ATC code N03) during pregnancy (yes/no); number of non-psychiatric hospital visits during pregnancy (0–1, 2–3 or 4); smoking during pregnancy (yes/no); marital status (married or cohabiting, single, divorced, widowed); highest education (mandatory education, above mandatory education); and calendar year of delivery (1997–2000, 2001–05, 2006 or 2011–15). Data on these covariates came from the registers mentioned above as well as from Statistics Denmark's registers on socioeconomic status.³⁷

Statistical analysis

Analyses were performed in Stata, version 16.0 (Stata Corp, College Station, TX) and SAS, version 9.4. We used random-effects logistic regression to estimate the odds ratios (ORs) and absolute risk differences of adverse birth outcomes (categorical outcomes), as well as

their 95% confidence intervals (CIs) with robust standard error estimation and mother's identity as a cluster variable, adjusting for the above-mentioned covariates.^{38,39} We also calculated the attributable fraction of antidepressants as the proportionate increase in the risk of adverse neonatal outcomes among the antidepressant exposure group using the following formula: $(p(\text{outcome}=1 | \text{expo}=1) - p(\text{outcome}=1 | \text{expo}=0)) / p(\text{outcome}=1 | \text{expo}=1)$. Random-effects generalized linear regression was employed to estimate the mean difference (β) of birthweight and gestational age (continuous outcomes).^{38,39} The comparisons were made between children in the antidepressant continuation group and children in the antidepressant discontinuation group. The rationale for this analysis is that individuals who discontinue antidepressants should be more comparable to individuals who continue antidepressants than individuals who never used antidepressants. This comparison group should control for some of the impact of the underlying psychiatric disorders. Data were missing in 7.0% of the participants for one or more potential confounders. We applied 20 imputations using the Markov Chain Monte Carlo technique for imputing missing values.⁴⁰

To examine whether the associations between antidepressant exposure and adverse birth outcomes depended on the timing of exposure, we divided the exposure window into three groups based on the last menstrual period: 1) first trimester only (one month before pregnancy to 90 days after last menstrual period); 2) second or third trimester only (91 to 180 days after last menstrual period or 181 days after last menstrual period to childbirth); and 3) more than one trimester. We considered a child to be exposed to antidepressants during a particular exposure window if the dispensing date fell within the window or if the number of days prescribed overlapped with that window. To study whether the associations varied with different classes of antidepressant, we categorized antidepressant treatment into i) SSRIs only, ii) non-SSRIs only and iii) both SSRIs and non-SSRIs. Types of preterm birth (extremely preterm, very preterm, moderate to late preterm and full-term birth), and types of low birthweight (very low birthweight, moderately low birthweight and healthy birthweight) were included as nominal variables where full-term birth and birthweight $>2,500\text{g}$ were considered the reference variables, respectively.

Results

Of the 1,138,515 children included in the study, 45,590 children born to mothers who used antidepressants in the year before pregnancy were included in the analyses (4.0% of the total sample). Among them, 21,914 were born to mothers who continued antidepressant treatment during pregnancy (1.9% of the total sample); 75.0% ($n=16,429$) of these mothers used SSRI monotherapy, 16.9% ($n=3,700$) used non-SSRI antidepressant monotherapy and 8.1% ($n=1,785$) used both SSRI and non-SSRI antidepressants. Mothers who continued antidepressants during pregnancy were older, more likely to have a psychiatric history, more likely to have had inpatient- or outpatient psychiatric treatment, and more likely to redeem other psychotropic and antiepileptic prescriptions during pregnancy. Table 1 lists the psychiatric and demographic characteristics of the study population.

Antidepressant exposure at any time during pregnancy

The mean gestational age of children in the continuation and discontinuation group was 274.6 days (SD=14.0) and 277.3 days (SD=13.5), respectively. The mean birthweight for the continuation was 3,403 g (SD=589); for the discontinuation group it was 3,468 g (SD=588). Antidepressant exposure during pregnancy was associated with a decrease in gestational age of 2.3 days (95% CI: -2.9; -2.0) and in birthweight of 51 g (95% CI: -62; -41).

The risks for several adverse birth outcomes were higher in the continuation group than the discontinuation group: adjusted OR (aOR)=1.43 (95% CI: 1.33; 1.55) for moderate to late preterm birth (32–37 weeks); aOR=1.28 (95% CI: 1.17; 1.41) for moderately low birthweight (1,500–2,499g); aOR=1.52 (95% CI: 1.44; 1.60) for neonatal admission; and aOR=2.59 (95% CI: 1.87; 3.59) for postnatal adaptation syndrome. Continuing antidepressant treatment in pregnancy did not increase the risk of the neonate being born extremely preterm (< 28 weeks), very preterm (28 to 32 weeks), very low birthweight (< 1,500 g) or small for gestational age. Continuing antidepressant treatment in pregnancy also did not increase the risk for congenital malformations in the child (Table 2). The most pronounced adjusted absolute risk difference was seen for neonatal admission (6.3%, 95% CI: 6.2%; 6.4%). Antidepressant effectiveness was 22.7%, suggesting that neonatal admissions were 22.7% higher in the antidepressant exposure group than they would have if they had not been exposed to maternal antidepressants during pregnancy. The predominant reasons for neonatal admission were i) conditions originating in the perinatal period (66.2%), ii) medical observation and evaluation for suspected diseases and conditions (14.6%), iii) symptoms, signs, and abnormal clinical and laboratory findings (4.6%) and iv) congenital malformations (3.6%).

Timing of antidepressant exposure

Exposure to antidepressants in the second or third trimester only was associated with a greater decrease in gestational age than antidepressant exposure in the first trimester only. The risks of other adverse birth outcomes did not differ by timing of exposure. However, children exposed to antidepressants in more than one trimester had the highest risk of very preterm birth, moderate to late preterm birth, low birthweight, neonatal admission and postnatal adaptation syndrome (Table 3).

Type of antidepressant exposure

Children exposed to non-SSRI monotherapy had a greater decrease in gestational age and birthweight than children exposed to SSRI monotherapy. Similarly, higher risks of preterm birth, low birthweight and neonatal admission were observed for children born to mothers treated with non-SSRI monotherapy than SSRI monotherapy, with the largest difference seen for preterm birth. The aOR for very preterm birth and moderate to late preterm birth was 0.98 (95% CI: 0.66; 1.45) and 0.98 (95% CI: 0.84; 1.13) for SSRI monotherapy, respectively, versus 1.86 (95% CI: 1.33; 2.59) and 2.08 (95% CI: 1.84; 2.35) for non-SSRI monotherapy, respectively. The risk for postnatal adaptation syndrome did not differ by type of antidepressant (Table 4).

Discussion

In this comprehensive prospective population-based study of the effects of intrauterine antidepressant exposure on the most commonly investigated neonatal outcomes³⁰, we found that antidepressant exposure during any point in pregnancy was associated with modest decreases in gestational age (2.3 days) and birthweight (51 g). In support of previously suggestive evidence,³⁰ we further demonstrated higher risk for moderate to late preterm birth (32 to 37 weeks), moderately low birthweight (1,500–2,499 g), postnatal adaptation syndrome and neonatal admission. Continuing antidepressant treatment in pregnancy did not increase the risk for the most severe neonatal outcomes, including being born extremely preterm (<28 weeks), very preterm (28 to 32 weeks), very low birthweight (<1,500 g), small for gestational age or with congenital malformations.

We suggest that the observed associations may be attributable to the severity of the underlying maternal disorders rather than intrauterine effects of the medication. Although the present register-based study does not have information on the severity of the underlying maternal disorder, analyses of timing and type of antidepressant exposure provide some insight into severity of the disorder. This idea is based on the assumptions that a) pregnant individuals with severe symptoms are more likely to continue treatment throughout pregnancy compared to individuals with milder forms of depression and/or anxiety who may decide to discontinue antidepressant use upon learning of their pregnancy⁴¹; and b) since SSRIs are the most commonly prescribed antidepressants, treatment with non-SSRI monotherapy may be associated with drug switching due to persistent symptoms, and limited or no treatment response⁴², and thus greater severity of the disorder. We found that children exposed to antidepressants in more than one trimester had the highest risk of very preterm birth (28 to 32 weeks), moderate to late preterm birth (32–37 weeks), low birthweight (1,500–2,499 g), neonatal admission and postnatal adaptation syndrome. Moreover, children exposed to non-SSRI monotherapy had a greater decrease in gestational age and birthweight than children exposed to SSRI monotherapy.

Strengths and limitations of study

We examined the association between prenatal exposure to antidepressants and neonatal outcomes in a large population-based sample using a random effects model. Comparing prenatally antidepressant-exposed individuals to individuals born to mothers who discontinued antidepressants before pregnancy may not completely address confounding by indication. Yet, applying a random effects model allowed us to estimate the marginal effect of antidepressant exposure in the entire population while accounting for family-level effects. This model may provide more accurate estimates of the effects of antidepressant exposure than previous work. Moreover, ascertainment and recall biases were reduced by the independent and prospective collection of exposure and outcome data in the Danish registries. Lastly, this study investigated a comprehensive list of the most commonly investigated birth and neonatal outcomes.³⁰

The following limitations must be considered. First, to define antidepressant exposure, we used prescription data. Some patients may fill prescriptions without actually taking the

antidepressants, leading to potential exposure misclassification. However, this is a limitation present in all observational pharmaco-epidemiological studies. Antidepressant treatment compliance during pregnancy is high in Denmark, so the extent of misclassification is likely to be small.⁴³ Second, unmeasured confounding cannot be ruled out, as in all observational studies. Third, it is currently unclear how generalisable our findings are to populations that differ from the Danish population, for example, with regards to cultural diversity or genetic makeup. Fourth, although our sample size is large, some subgroup analyses are based on a small number of cases. Fifth, potential mediators, such as psychotropic and antiepileptic prescriptions, may be misclassified as covariates. However, here we used the presence of these prescriptions as proxies for comorbid conditions, as is common in pharmaco-epidemiological research.^{44,45} Moreover, we may be underestimating the effect of second and third trimester exposure on preterm birth because of immortal time bias, i.e., the error in estimating the association between the exposure and the outcome that results from the exclusion of time intervals.⁴⁶ However, it is important to note that 20,259 (94.7%) of children in our study were exposed to antidepressants in the first trimester. Therefore, the influence of immortal time bias is likely minimal in this study. Lastly, registers do not contain information on disorder severity⁴⁷ and it is conceivable that individuals who continue antidepressant use throughout one pregnancy have more severe symptoms in that pregnancy than during another pregnancy or compared to individuals who discontinue⁴¹. Although we aimed to limit the effects of the underlying confounding by indication (by comparing individuals who discontinue antidepressant to individuals who used antidepressants throughout pregnancy and controlling for important psychiatric confounders, e.g., psychiatric history, inpatient and outpatient psychiatric treatment, prescriptions for other psychotropic drugs), confounding by severity may still be present.

In conclusion, this large prospective population-based register study investigating a comprehensive list of the most commonly studied neonatal outcomes associated with prenatal exposure to antidepressants provides evidence for an association between prenatal antidepressant use and small decreases in gestational age and birthweight, as well as higher risk for moderate to late preterm birth, moderately low birthweight, neonatal admission and postnatal adaptation syndrome. The causality of the observed associations is far from established due to the probability of unmeasured residual confounding linked to the underlying disease. Nonetheless, the potential risks related to antidepressant use during pregnancy should be explained to antidepressant-treated individuals who wish to conceive or who discover their pregnancy to allow an informed decision. Individuals may then weigh up the risks and benefits for themselves in tandem with their treating physician.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Financial support:

This study is supported by the National Institute of Mental Health (NIMH) (R01MH122869). Dr Liu is also supported by the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 891079. Dr Munk-Olsen is also supported by iPSYCH, the

Lundbeck Foundation Initiative for Integrative Psychiatric Research (R155-2014-1724), the Lundbeck Foundation (R313-2019-569), AUFF NOVA (AUFF-E 2016-9-25), and Fabrikant Vilhelm Pedersen og Hustrus Legat. The funders of the study had no role in study design, data analysis, data interpretation, writing, or submission for publication.

Data availability:

Data are not publicly available.

References

1. Woody CA, Ferrari AJ, Siskind DJ, Whiteford HA, Harris MG. A systematic review and meta-regression of the prevalence and incidence of perinatal depression. *J Affect Disord.* 2017;219:86–92. doi:10.1016/J.JAD.2017.05.003 [PubMed: 28531848]
2. Jarde A, Morais M, Kingston D, et al. Neonatal outcomes in women with untreated antenatal depression compared with women without depression: A systematic review and meta-analysis. *JAMA Psychiatry.* 2016;73(8):826–837. doi:10.1001/jamapsychiatry.2016.0934 [PubMed: 27276520]
3. Talge NM, Neal C, Glover V, Early Stress, Translational Research and Prevention Science Network: Fetal and Neonatal Experience on Child and Adolescent Mental Health. Antenatal maternal stress and long-term effects on child neurodevelopment: how and why? *J Child Psychol Psychiatry.* 2007;48(3–4):245–261. <https://acamh.onlinelibrary.wiley.com/doi/full/10.1111/j.1469-7610.2006.01714.x>. Accessed August 30, 2019. [PubMed: 17355398]
4. Olfson M, Blanco C, Marcus SC. Treatment of Adult Depression in the United States. *JAMA Intern Med.* 2016;176(10):1482–1491. doi:10.1001/JAMAINTERNMED.2016.5057 [PubMed: 27571438]
5. Pratt L, Brody D, Gu Q. Antidepressant Use Among Persons Aged 12 and Over: United States, 2011–2014. *NCHS Data Brief.* 2017;283:1–8.
6. Charlton R, Jordan S, Pierini A, et al. Selective serotonin reuptake inhibitor prescribing before, during and after pregnancy: a population-based study in six European regions. *BJOG.* 2015;122(7):1010–1020. doi:10.1111/1471-0528.13143 [PubMed: 25352424]
7. Ewing G, Tatarchuk Y, Appleby D, Schwartz N, Kim D. Placental Transfer of Antidepressant Medications: Implications for Postnatal Adaptation Syndrome. *Clin Pharmacokinet.* 2015;54(4):359–370. doi:10.1007/s40262-014-0233-3 [PubMed: 25711391]
8. Hanley GE, Mintzes B. Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance. *BMC Pregnancy Childbirth* 2014 141. 2014;14(1):1–12. doi:10.1186/1471-2393-14-242
9. Huang H, Coleman S, Bridge JA, Yonkers K, Katon W. A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight. *Gen Hosp Psychiatry.* 2014;36(1):13–18. doi:10.1016/J.GENHOSPSPSYCH.2013.08.002 [PubMed: 24094568]
10. Kautzky A, Slamanig R, Unger A, Höflich A. Neonatal outcome and adaptation after in utero exposure to antidepressants: A systematic review and meta-analysis. *Acta Psychiatr Scand.* 2022;145(1):6–28. doi:10.1111/ACPS.13367 [PubMed: 34486740]
11. Masarwa R, Bar-Oz B, Gorelik E, Reif S, Perlman A, Matok I. Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis. *Am J Obstet Gynecol.* 2019;220(1):57.e1–57.e13. doi:10.1016/J.AJOG.2018.08.030
12. Nembhard WN, Tang X, Hu Z, Macleod S, Stowe Z, Webber D. Maternal and infant genetic variants, maternal periconceptional use of selective serotonin reuptake inhibitors, and risk of congenital heart defects in offspring: population based study. *BMJ.* 2017;356. doi:10.1136/BMJ.J832
13. Huybrechts KF, Bateman BT, Palmsten K, et al. Antidepressant Use Late in Pregnancy and Risk of Persistent Pulmonary Hypertension of the Newborn. *JAMA.* 2015;313(21):2142–2151. doi:10.1001/JAMA.2015.5605 [PubMed: 26034955]

14. Gao S-Y, Wu Q-J, Sun C, et al. Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births. *BMC Med* 2018 16(1):1–14. doi:10.1186/S12916-018-1193-5
15. Grove K, Lewis AAJ, Galbally M. Prenatal Antidepressant Exposure and Child Motor Development: A Meta-analysis. *Pediatrics*. 2018;142(1). <https://pubmed.ncbi.nlm.nih.gov/29929995/>. Accessed October 8, 2020.
16. Fitton CA, Steiner MFC, Aucott L, et al. In utero exposure to antidepressant medication and neonatal and child outcomes: a systematic review. *Acta Psychiatr Scand*. 2020;141(1):21–33. doi:10.1111/ACPS.13120 [PubMed: 31648376]
17. Yang A, Ciolino JD, Pinheiro E, Rasmussen-Torvik LJ, Sit DKY, Wisner KL. Neonatal Discontinuation Syndrome in Serotonergic Antidepressant-Exposed Neonates. *J Clin Psychiatry*. 2017;78(5):605–611. doi:10.4088/JCP.16M11044 [PubMed: 28570796]
18. Huybrechts KF, Sanghani RS, Avorn J, Urato AC. Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis. *PLoS One*. 2014;9(3). doi:10.1371/JOURNAL.PONE.0092778
19. Ross LE, Grigoriadis S, Mamisashvili L, et al. Selected Pregnancy and Delivery Outcomes After Exposure to Antidepressant Medication. *JAMA Psychiatry*. 2013;70(4):436. doi:10.1001/jamapsychiatry.2013.684 [PubMed: 23446732]
20. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. *J Clin Psychiatry*. 2013;74(04):e309–e320. doi:10.4088/JCP.12r07967 [PubMed: 23656856]
21. Steinhorn RH. Neonatal pulmonary hypertension. *Pediatr Crit Care Med*. 2010;11(2 Suppl). doi:10.1097/PCC.0B013E3181C76CDC
22. Casper RC, Gilles AA, Fleisher BE, Baran J, Enns G, Lazzeroni LC. Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development. *Psychopharmacology (Berl)*. 2011;217(2):211–219. doi:10.1007/S00213-011-2270-Z [PubMed: 21499702]
23. Malm H, Sourander A, Gissler M, et al. Pregnancy Complications Following Prenatal Exposure to SSRIs or Maternal Psychiatric Disorders: Results From Population-Based National Register Data. *Am J Psychiatry*. 2015;172(12):1224–1232. doi:10.1176/appi.ajp.2015.14121575 [PubMed: 26238606]
24. Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant Use in Pregnancy and the Risk of Cardiac Defects. *N Engl J Med*. 2014;370(25):2397–2407. <http://www.ncbi.nlm.nih.gov/pubmed/24941178>. Accessed October 19, 2018. [PubMed: 24941178]
25. Nordeng H, Van Gelder MMHJ, Spigset O, Koren G, Einarson A, Eberhard-Gran M. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study. *J Clin Psychopharmacol*. 2012;32(2):186–194. doi:10.1097/JCP.0B013E3182490EAF [PubMed: 22367660]
26. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. *JAMA*. 1998;279(8):609–610. doi:10.1001/JAMA.279.8.609 [PubMed: 9486756]
27. Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. *Acta Psychiatr Scand*. 2013;127(2):94–114. <https://pubmed.ncbi.nlm.nih.gov/23240634/>. Accessed December 5, 2018. [PubMed: 23240634]
28. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. *N Engl J Med*. 2007;356(26):2675–2683. doi:10.1056/NEJMOA067407 [PubMed: 17596601]
29. Greene MF. Teratogenicity of SSRIs--serious concern or much ado about little? *N Engl J Med*. 2007;356(26):2732–2733. doi:10.1056/NEJME078079 [PubMed: 17596609]
30. Biffi A, Cantarutti A, Rea F, Locatelli A, Zanini R, Corrao G. Use of antidepressants during pregnancy and neonatal outcomes: An umbrella review of meta-analyses of observational studies. *J Psychiatr Res*. 2020;124:99–108. doi:10.1016/J.JPSYCHIRES.2020.02.023 [PubMed: 32135392]

31. Thygesen LC, Daasnes C, Thaulow I, Brønnum-Hansen H. Introduction to Danish (nationwide) registers on health and social issues: Structure, access, legislation, and archiving. *Scandinavian J Public Heal.* 2011;39(7):12–16. doi:10.1177/1403494811399956
32. Pedersen CB. The Danish Civil Registration System. *Scand J Public Health.* 2011;39(7):22–25. doi:10.1177/1403494810387965 [PubMed: 21775345]
33. Bliddal M, Broe A, Pottegård A, Olsen J, Langhoff-Roos J. The Danish Medical Birth Register. *Eur J Epidemiol.* 2018;33(1):27–36. doi:10.1007/S10654-018-0356-1 [PubMed: 29349587]
34. Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data Resource Profile: The Danish National Prescription Registry. *Int J Epidemiol.* 2017;46(3):798–798f. doi:10.1093/IJE/DYW213 [PubMed: 27789670]
35. Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. *Clin Epidemiol.* 2015;7:449–490. doi:10.2147/CLEP.S91125 [PubMed: 26604824]
36. Mors O, Perto GP, Mortensen PB. The Danish Psychiatric Central Research Register: *Scand J Public Health.* 2011;39(7):54–57. doi:10.1177/1403494810395825 [PubMed: 21775352]
37. Petersson F, Baadsgaard M, Thygesen LC. Danish registers on personal labour market affiliation. *Scand J Public Health.* 2011;39(7):95–98. doi:10.1177/1403494811408483 [PubMed: 21775363]
38. Neuhaus JM, Kalbfleisch JD. Between- and Within-Cluster Covariate Effects in the Analysis of Clustered Data. *Biometrics.* 1998;54(2):638. doi:10.2307/3109770 [PubMed: 9629647]
39. Begg MMD, Parides MKM. Separation of individual-level and cluster-level covariate effects in regression analysis of correlated data. *Stat Med.* 2003;22(16):2591–2602. <https://pubmed.ncbi.nlm.nih.gov/12898546/>. Accessed June 4, 2021. [PubMed: 12898546]
40. Royston P, White IR. Multiple imputation by chained equations (MICE): Implementation in Stata. *J Stat Softw.* 2011;45(4):1–20. doi:10.18637/jss.v045.i04
41. Patten SB. Confounding by severity and indication in observational studies of antidepressant effectiveness. *Can J Clin Pharmacol.* 2008;15(2):e367–e371. <https://jptcp.com/index.php/jptcp/article/view/209>. Accessed November 18, 2020. [PubMed: 18840922]
42. Vigod SN, Wilson CA, Howard LM. Depression in pregnancy. *BMJ.* 2016;352. doi:10.1136/bmj.i1547
43. Olesen C, Søndergaard C, Thrane N, Lauge Nielsen G, De Jong-Van Den Berg L, Olsen J. Do pregnant women report use of dispensed medications? *Epidemiology.* 2001;12(5):497–501. doi:10.1097/00001648-200109000-00006 [PubMed: 11505166]
44. Paterno E, Huybrechts KF, Bateman BT, et al. Lithium Use in Pregnancy and the Risk of Cardiac Malformations. *N Engl J Med.* 2017;376(23):2245–2254. doi:10.1056/NEJMOA1612222/SUPPL_FILE/NEJMOA1612222_DISCLOSURES.PDF [PubMed: 28591541]
45. Christensen J, Trabjerg BB, Sun Y, Dreier JW. Association of Maternal Antidepressant Prescription During Pregnancy With Standardized Test Scores of Danish School-aged Children. *JAMA.* 2021;326(17):1725–1735. doi:10.1001/JAMA.2021.17380 [PubMed: 34726709]
46. Suissa S. Immortal Time Bias in Pharmacoepidemiology. *Am J Epidemiol.* 2008;167(4):492–499. doi:10.1093/AJE/KWM324 [PubMed: 18056625]
47. Palmsten K, Hernández-Díaz S. Can nonrandomized studies on the safety of antidepressants during pregnancy convincingly beat confounding, chance, and prior beliefs? *Epidemiology.* 2012;23(5):686–688. doi:10.1097/EDE.0b013e318258fbb2 [PubMed: 22872113]

Significant Outcomes:

1. Antidepressant exposure during any point in pregnancy was associated with modest decreases in gestational age of ~ 2 days and in birthweight of ~ 51 g.
2. Antidepressant exposure during any point in pregnancy was also associated with increased risk for moderate to late preterm birth (32 to 37 weeks), moderately low birthweight (1,500–2,499 g), postnatal adaptation syndrome and neonatal admission.
3. Continuing antidepressant treatment in pregnancy did not increase the risk for the most severe neonatal outcomes, including being born extremely preterm (< 28 weeks), very preterm (28 to 32 weeks), very low birthweight (< 1,500 g), small for gestational age or with congenital malformations.

Limitations:

1. Unmeasured confounding, particularly confounding by indication cannot be ruled out. Registers do not contain information on disorder severity and it is conceivable that individuals who continue antidepressant use throughout one pregnancy have more severe symptoms than in another episode during another pregnancy or compared to individuals who discontinue.
2. Prescription data were used to define antidepressant exposure. Some patients may fill prescriptions without actually taking the antidepressants, leading to potential exposure misclassification.
3. While our sample size is large, some subgroup analyses are based on a small number of cases.




Figure 1. Flow chart illustrating the identification of the study population

Table 1.

Characteristics of study population according to maternal antidepressant use before and during pregnancy. Values are numbers (percentages) unless stated otherwise

Characteristics	Antidepressant continuation group (N=21,914)		Antidepressant discontinuation group (N=23,676)	
	n	%	n	%
Maternal age at delivery, years				
<25	2,939	13.4	4,354	18.4
25–34	13,710	62.6	14,841	62.7
35	5,265	24.0	4,481	18.9
Primiparity	9,937	45.3	10,812	45.7
Maternal psychiatric history at delivery	11,106	50.7	7,910	33.4
Maternal inpatient psychiatric treatment from 1 year before pregnancy to delivery	1,124	5.1	697	2.9
Maternal outpatient psychiatric treatment from 1 year before pregnancy to delivery	5,728	26.1	3,662	15.5
Psychotropic prescriptions during pregnancy	3,398	15.5	1,352	5.7
Antiepileptic prescriptions during pregnancy	927	4.2	326	1.4
Number of maternal non-psychiatric hospital visits during pregnancy				
0–1	4,301	19.6	4,749	20.1
2–3	9,644	44.0	10,497	44.3
4	7,969	36.4	8,430	35.6
Maternal smoking during pregnancy				
Yes	6,186	28.2	6,650	28.1
No	14,833	67.7	15,688	66.3
Missing	895	4.1	1,338	5.7
Maternal marital status at delivery				
Married or cohabiting	16,854	76.9	18,058	76.3
Single, divorced, or widowed	5,027	22.9	5,555	23.5
Missing	33	0.2	63	0.3
Maternal highest education at delivery				
Mandatory education	6,405	29.2	7,935	33.5
Above mandatory education	15,064	68.7	15,164	64.1
Missing	445	2.0	577	2.4
Calendar year of delivery				
1997–2000	1,237	5.6	2,297	9.7
2001–2005	4,053	18.5	5,370	22.7
2006–2010	8,283	37.8	7,631	32.2
2011–2015	8,341	38.1	8,378	35.4
Sex of child				

Characteristics	Antidepressant continuation group (N=21,914)		Antidepressant discontinuation group (N=23,676)	
	n	%	n	%
Male	11,318	51.6	12,163	51.4
Female	10,596	48.4	11,513	48.6

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2.

Crude and adjusted odds ratio and adjusted absolute risk difference of adverse birth outcomes among children born to mothers with continuous antidepressant use, compared with mothers with discontinuous antidepressant use

Birth outcomes	Continuation group (N=21,914) †	Discontinuation group (N=23,676) †	Crude analysis	Adjusted analysis	aAbsolute risk difference
	Mean (SD)	Mean (SD)	β (95% CI)	β (95% CI)	% (95% CI)
Gestational age (days) ‡	274.6 (14.0)	277.3 (13.5)	-2.7 (-2.9; -2.4)	-2.3 (-2.6; -2.0)	-
Birthweight (g) ‡	3,402.7 (589.4)	3,468.1 (587.6)	-66.1 (-76.9; -55.3)	-51.3 (-62.2; -40.5)	-
	n (%)	n (%)	OR (95% CI)	OR (95% CI)	% (95% CI)
Extremely preterm (<28 weeks)	56 (0.3)	63 (0.3)	0.99 (0.69; 1.41)	0.90 (0.61; 1.32)	0 (-0.1; 0.1)
Very preterm (28–32 weeks)	174 (0.8)	163 (0.7)	1.18 (0.96; 1.47)	1.18 (0.95; 1.47)	0.1 (-0.1; 0.3)
Moderate to late preterm (32–37 weeks)	1,673 (7.6)	1,251 (5.3)	1.48 (1.38; 1.60)	1.43 (1.33; 1.55)	2.1 (1.7; 2.6)
Very low birthweight (<1,500 g)	178 (0.8)	192 (0.8)	1.01 (0.83; 1.24)	1.00 (0.81; 1.24)	0 (-0.2; 0.2)
Moderately low birthweight (1,500–2,499g)	1,105 (5.0)	315 (3.9)	1.32 (1.21; 1.44)	1.28 (1.17; 1.41)	1.0 (0.7; 1.4)
Small for gestational age	2,500 (11.4)	2,675 (11.3)	1.04 (0.96; 1.13)	0.99 (0.91; 1.08)	-0.1 (-0.1; 0)
Postnatal adaptation syndrome	228 (1.0)	67 (0.3)	3.92 (2.89; 5.31)	2.59 (1.87; 3.59)	0.5 (0.4; 0.6)
Persistent pulmonary hypertension of the neonate	59 (0.3)	44 (0.2)	1.45 (0.98; 2.14)	1.26 (0.86; 1.87)	0.1 (0.0; 0.1)
Neonatal admission	5,907 (27.0)	4,523 (19.1)	1.67 (1.58; 1.76)	1.52 (1.44; 1.60)	6.3 (6.2; 6.4)
Congenital malformations	970 (4.4)	990 (4.2)	1.06 (0.97; 1.17)	1.03 (0.94; 1.14)	0.1 (-0.3; 0.5)

OR= odds ratio; aAbsolute risk difference= adjusted absolute risk difference; Adjusted for maternal age at delivery, primiparity, maternal psychiatric history at delivery, maternal inpatient and outpatient treatment from 1 year before pregnancy to delivery, dispensing of other psychotropic prescriptions during pregnancy, dispensing of antiepileptic prescriptions during pregnancy, number of maternal non-psychiatric hospital visits during pregnancy, smoking during pregnancy, marital status at delivery, highest education at delivery, and calendar year of delivery.

† Values are numbers of cases (percentages) unless stated otherwise.

‡ Crude and adjusted mean differences, β-coefficients were estimated for gestational age and birth weight as continuous variables.

Table 3.

Adjusted odds ratio and absolute risk difference of adverse birth outcomes among children of mothers with continued antidepressant use, compared with mothers with discontinued antidepressant use by the timing of antidepressant exposure

Birth outcomes	1 st trimester only (N=4,362) *		2 nd or 3 rd trimester only (N=597) *		More than one trimester (N=16,955)	
	aOR β (95% CI)	aAbsolute risk difference % (95% CI)	aOR β (95% CI)	aAbsolute risk difference % (95% CI)	aOR β (95% CI)	aAbsolute risk difference % (95% CI)
Gestational age (days) [†]	-0.1 (-0.6; -0.3)	-	-1.4 (-2.5; -0.4)	-	-3.0 (-3.3; -2.7)	-
Birth weight (g) [†]	5.1 (-13.2; 23.3)	-	-29.9 (-74.8; 15.0)	-	-70.3 (-82.2; -58.5)	-
Extremely preterm (<28 weeks) [‡]	1.10 (0.60; 2.03)	0.0 (-0.2; 0.2)	-	-	0.82 (0.54; 1.24)	-0.1 (-0.2; 0.1)
Very preterm (28–32 weeks) [‡]	0.98 (0.66; 1.45)	0.0 (-0.3; 0.3)	-	-	1.28 (1.02; 1.62)	0.2 (0.0; 0.3)
Moderate to late preterm (32–37 weeks)	0.98 (0.84; 1.13)	-0.1 (-0.8; 0.6)	1.19 (0.85; 1.66)	0.9 (-1.0; 2.9)	1.59 (1.46; 1.72)	2.8 (2.3; 3.3)
Very low birthweight (<1500 g)	0.93 (0.64; 1.36)	-0.1 (-0.3; 0.2)	1.06 (0.43; 2.59)	0.0 (-0.7; 0.8)	1.02 (0.80; 1.29)	0.0 (-0.2; 0.2)
Low birthweight (1500–2499g)	1.02 (0.86; 1.20)	0.1 (-0.6; 0.7)	1.12 (0.75; 1.68)	0.5 (-1.2; 2.1)	1.37 (1.24; 1.52)	1.4 (0.9; 1.8)
Small for gestational age	0.98 (0.85; 1.12)	-0.2 (-0.7; 0.3)	0.97 (0.68; 1.38)	-0.2 (-2.3; 1.9)	1.00 (0.91; 1.09)	0.0 (-0.1; 0.1)
Postnatal adaptation syndrome [‡]	1.47 (0.88; 2.46)	0.2 (-0.1; 0.3)	-	-	2.99 (2.12; 4.22)	0.6 (0.5; 0.7)
Neonatal admission	0.99 (0.90; 1.09)	0.0 (-0.8; 0.7)	1.28 (1.03; 1.59)	3.6 (0.8; 6.3)	1.71 (1.61; 1.81)	8.3 (8.1; 8.5)
Congenital malformations	1.10 (0.94; 1.30)	-0.1 (-0.3; 0.2)	0.84 (0.54; 1.32)	-0.2 (-0.7; 0.3)	1.02 (0.92; 1.13)	0.1 (-0.1; 0.2)

Children born to mothers who discontinued antidepressants were the comparison group.

* 1st trimester only—one month before pregnancy to 90 days after last menstrual period); 2nd or 3rd trimester only—91–180 days after last menstrual period or 181 days after last menstrual period to childbirth.

OR= odds ratio; aOR= adjusted odds ratio; aAbsolute risk difference= adjusted absolute risk difference; Adjusted for maternal age at delivery, primiparity, maternal psychiatric history at delivery, maternal inpatient and outpatient treatment from 1 year before pregnancy to delivery, dispensing of other psychotropic prescriptions during pregnancy, dispensing of antiepileptic prescriptions during pregnancy, number of maternal non-psychiatric hospital visits during pregnancy, smoking during pregnancy, marital status at delivery, highest education at delivery, and calendar year of delivery.

[†] Adjusted mean differences, β -coefficients were estimated for gestational age and birth weight as continuous variables.

[‡] Less than 5 outcomes and thus cannot provide an accurate estimate for 2nd or 3rd exposure only.

The numbers of cases of persistent pulmonary hypertension in neonates were too small to estimate trimester-specific effect.

Table 4.

Adjusted odds ratio and absolute risk difference of adverse birth outcomes among children of mothers with continued antidepressant use, compared with mothers with discontinued antidepressant use by type of antidepressant exposure

Birth outcomes	SSRIs only (N=16,429) *		Non-SSRIs only (N=3,700) *		SSRIs and non-SSRIs (N=1,785) *	
	aOR β (95% CI)	aAbsolute risk difference % (95% CI)	aOR β (95% CI)	aAbsolute risk difference % (95% CI)	aOR β (95% CI)	aAbsolute risk difference % (95% CI)
Gestational age (days) †	-1.8 (-2.1; -1.6)	-	-4.0 (-4.6; -3.5)	-	-3.3 (-4.0; -2.6)	-
Birthweight (g) †	-45.8 (57.3; -34.2)	-	-67.6 (-89.1; -46.0)	-	-73.8 (-101.7; -45.8)	-
Extremely preterm (<28 weeks)	0.82 (0.53; 1.25)	-0.1 (-0.2; 0.1)	1.31 (0.71; 2.42)	0.1 (-0.1; 0.3)	0.90 (0.35; 2.32)	-0.1 (-0.3; 0.2)
Very preterm (28–32 weeks)	1.05 (0.82; 1.34)	0.0 (-0.2; 0.2)	1.86 (1.33; 2.59)	0.5 (0.1; 0.9)	1.18 (0.68; 2.02)	0.1 (-0.3; 0.5)
Moderate to late preterm (32–37 weeks)	1.28 (1.18; 1.39)	1.4 (0.9; 1.9)	2.08 (1.84; 2.35)	5.0 (4.0; 6.0)	1.66 (1.39; 1.98)	3.2 (1.9; 4.5)
Very low birthweight (<1500 g)	0.95 (0.75; 1.20)	-0.1 (-0.2; 0.1)	1.27 (0.89; 1.80)	0.2 (-0.2; 0.5)	0.98 (0.57; 1.68)	0.0 (-0.5; 0.4)
Low birthweight (1500–2499g)	1.20 (1.08; 1.32)	0.7 (0.3; 1.1)	1.61 (1.39; 1.87)	2.2 (1.4; 3.0)	1.40 (1.13; 1.74)	1.5 (0.4; 2.5)
Small for gestational age	0.99 (0.91; 1.08)	-0.1 (-0.1; 0.0)	0.97 (0.80; 1.13)	-0.2 (-0.8; 0.4)	1.04 (0.85; 1.28)	0.3 (-0.8; 1.3)
Postnatal adaptation syndrome	2.51 (1.79; 3.50)	0.5 (0.3; 0.6)	3.05 (1.91; 4.87)	0.6 (0.4; 0.8)	2.48 (1.49; 4.13)	0.5 (0.2; 0.7)
Persistent pulmonary hypertension of the neonate	1.16 (0.75; 1.79)	0.0 (-0.1; 0.1)	1.57 (0.86; 2.88)	0.1 (-0.1; 0.3)	1.57 (0.72; 3.42)	0.1 (-0.1; 0.3)
Neonatal admission	1.43 (1.35; 1.51)	5.3 (5.1; 5.4)	1.85 (1.68; 2.03)	9.7 (8.7; 10.6)	1.79 (1.57; 2.03)	9.0 (7.5; 10.5)
Congenital malformations	1.01 (0.91; 1.12)	0.0 (-0.4; 0.4)	1.13 (0.95; 1.34)	0.5 (-0.2; 1.2)	1.10 (0.86; 1.40)	0.4 (-0.6; 1.4)

Children born to mothers who discontinued antidepressants were the comparison group.

* SSRIs only—Children born to mothers who used selective serotonin reuptake inhibitors during pregnancy

Non-SSRIs —Children born to mothers who used non-selective serotonin reuptake inhibitors during pregnancy

SSRIs and non-SSRIs—Children born to mothers who used both SSRIs and non-SSRIs during pregnancy, which could be due to switching or polytherapy.

OR= odds ratio; aOR= adjusted odds ratio; aAbsolute risk difference= adjusted absolute risk difference; Adjusted for maternal age at delivery, primiparity, maternal psychiatric history at delivery, maternal inpatient and outpatient treatment from 1 year before pregnancy to delivery, dispensing of other psychotropic prescriptions during pregnancy, dispensing of antiepileptic prescriptions during pregnancy, number of maternal non-psychiatric hospital visits during pregnancy, smoking during pregnancy, marital status at delivery, highest education at delivery, and calendar year of delivery.

† Adjusted mean differences, β -coefficients were estimated for gestational age and birth weight as continuous variables.